Cero Therapeutics Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 9, 2023 and accepted by EDGAR at Nov 9, 2023, 21:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 3 months2023-07-01 to 2023-09-30 | −$429.8k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-01-01 to 2023-09-30 | −$2.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-07-01 to 2023-09-30 | $25.8k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-01-01 to 2023-09-30 | $70.4k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-01 to 2023-09-30 | −$334.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-01-01 to 2023-09-30 | −$2.3m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2023-01-01 to 2023-09-30 | −$1.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 9 months2023-01-01 to 2023-09-30 | $5.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-09-30 | $119.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Total assets | At period end2023-09-30 | $8.5m | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $4.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $14.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-09-30 | −$13.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-23-085200. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.